Project

A-TANGO: Novel combinatorial treatment of acute-on-chronic liver failure

Goal: About 30,000 Europeans die every year from alcohol-related cirrhosis. In its final stages, the disease leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Scientific Coordination: Prof. Dr. Rajiv Jalan
Principal Investigator: Dr. med. Cornelius Engelmann
Science Communication: Dr. Nina Donner
Project Management: concentris research management gmbh

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945096. This project log reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.

Date: 1 March 2021

Updates
0 new
43
Recommendations
0 new
1
Followers
0 new
14
Reads
1 new
287

Project log

Nina C Donner
added an update
Come meet us at lunchtime at the CIRRHOSIS & COMPLICATIONS NETWORKING TRACK HUB on Friday, 24 June, for this joint networking event of three Horizon2020-funded liver research projects on ACLF at ILC 2022 in London.
 
Nina C Donner
added an update
Come meet us at lunchtime on Friday, 24 June, for this joint event of 3 Horizon2020-funded liver research projects on ACLF at ILC 2022 in London!
 
Nina C Donner
added an update
Come meet us at lunchtime on Friday, 24 June, for this joint event of 3 Horizon2020-funded liver research projects on ACLF at ILC2022 in London!
 
Nina C Donner
added an update
As today's final speaker at the Falk Foundation Symposium on the "Pathophysiology and Clinical Management of Alcoholic Liver Disease", A-TANGO coordinator Prof. Rajiv Jalan from UCL, gave an overview of potential new therapies (including G-TAK) that are currently in development and discussed crucial questions regarding the recovery from ACLF with the chairman of Session 2, Prof. Jonel Trebicka.
 
Nina C Donner
added an update
Register for FREE now for next week's Alcoholic Liver Disease symposium! From our 3 EU-funded cirrhosis projects, these experts are either speakers or organizers: Aleksander Krag, Rajiv Jalan, Jonel Trebicka, Sophie Lotersztajn, Richard Moreau
 
Nina C Donner
added an update
The 1st A-TANGO Newsletter is out - Learn about the project's progress, our early-career scientists (ECS), this year's patient event about cirrhosis and ACLF, upcoming scientific conferences, and let us wish you Happy Holidays & a healthy New Year!
 
Nina C Donner
added an update
You can also find us on LinkedIn!
 
Nina C Donner
added an update
Don't forget to also follow A-TANGO on Twitter!
 
Nina C Donner
added an update
To receive A-TANGO news on the project's progress, new team members, upcoming events, and a novel treatment for decompensated cirrhosis and ACLF, called "G-TAK", please subscribe to our half-yearly newsletter!
 
Nina C Donner
added an update
In the December edition of the "Journal of Hepatology Reports", A-TANGO early-career scientist Dr. Annarein Kerbert from Leiden University Medical Center and colleagues describe new findings on a disrupted turnover of collagen type III and VI in ACLF in association with the severity of liver dysfunction and inflammation. Have a look!
 
Nina C Donner
added an update
The A-TANGO info brochure is now available in 4 more languages (DE, ES, FR, NL), each in a print + web version. Feel free to download, print, and share! We are getting ready for the G-TAK study to treat ACLF, occurring in late-stage cirrhosis.
 
Nina C Donner
added an update
"Because [...] combination therapy with a TLR4 inhibitor may prevent G-CSF-associated inflammation and organ damage while promoting regeneration, a phase II trial is currently being prepared for patients with severe alcoholic hepatitis and ACLF."
 
Nina C Donner
added an update
Just out: A-TANGO's scientific coordinator, Prof. Dr. Rajiv Jalan, and colleagues published an insightful and very topical review paper on Cirrhosis-Associated Immune Dysfunction (CAID) in the journal "Nature Reviews Gastroenterology & Hepatology" this week. This review paper might be of particular interest to our early-career scientists (ECS)!
 
Nina C Donner
added an update
Congrats to the entire A-TANGO team for achieving these major steps forward to fight cirrhosis with the novel combinatorial therapy G-TAK! The hard work and team effort of the first project months have already paid off - despite the challenges we all face due to the pandemic.
 
Nina C Donner
added an update
Cirrhosis slows blood flow and puts stress on the portal vein, a major blood vessel carrying blood to the liver. This causes high blood pressure, aka "portal hypertension". At the current Baveno VII consensus workshop, hepatologists from around the world address this issue with a strong focus on personalized care!
 
Nina C Donner
added an update
Watch our introductory video about the G-TAK therapy for ACLF - recorded at a joint event that informed representatives of the European Liver Patients'​ Association about A-TANGO (https://a-tango.eu/) and two related Horizon2020-funded cirrhosis projects, namely DECISION (https://decision-for-liver.eu/) and MICROB-PREDICT (https://microb-predict.eu/).
 
Nina C Donner
added an update
The new A-TANGO website is online: Have a look and cruise through the different sections for cirrhosis patients, hepatologists, researchers, and trainees. News & events keep you in the loop!
 
Nina C Donner
added an update
The ‘Helix’ will form a community hub of peers that allows you to collaborate and also follow the A-TANGO project’s progress, activities, and results. Within the Helix, you can share and join specific collaboration opportunities related to cirrhosis, ACLF, and liver health. You can also invite stakeholders outside of the network who may be interested in this field. Join the Liver Health Helix (https://www.crowdhelix.com/helixes/liver-health) and click “Follow”. You will then be notified of new opportunities according to your chosen interests.
 
Nina C Donner
added an update
A-TANGO's coordinator Prof. Rajiv Jalan was very happy to announce at today's interactive debate "Is the term and the concept of ACLF useful in clinical practice?" at #ILC2021 that the UK and Spain now, too, have agreed to recommend cirrhosis patients in disease stages ACLF-2 and ACLF-3 for liver transplantation to save their lives. This addresses a long-standing inequity between European countries!
 
Nina C Donner
added an update
Patients with decompensated cirrhosis or ACLF can currently be categorized into 6 disease stages or pathophysiological phenotypes. A consensus of today's debate "Is the term and the concept of ACLF useful in clinical practice?" (Saturday, 26th June 2021, 2-3 pm CET) at #ILC2021 was that ACLF is very useful as a prognostic tool, but deeper understanding of the why & how is needed in order to increase the survival rate and to optimize clinical treatment of cirrhosis patients that have entered this dangerous decompensation stage of the disease (when the body can no longer compensate for the progressed scarring of the liver and all the other changes in the body that go along with that).
 
Nina C Donner
added an update
ILC 2021 starts tomorrow - You can learn more about the A-TANGO project at the booth of EU-funded projects (https://easl.eu/ilc-2021/eu-projects/) and on SATURDAY at 14:04 CET in Rajiv Jalan's presentation during the interactive session "Cirrhosis and complications". We hope to see you there!
 
Nina C Donner
added an update
During his talk at this week's patient event (organised by ELPA, the European Liver Patients' Association), Dr. med. Cornelius Engelmann from the Charité described the early (reversible) and the late (irreversible) stages of alcoholic liver disease, leading first to steatosis, then to fibrosis, and eventually cirrhosis.
 
Nina C Donner
added an update
Currently, only 2 drugs are available to treat patients with late-stage liver disease, such as decompensated cirrhosis or ACLF, while more than 2 million people die of chronic liver disease every year. It's time, we do something about it!
 
Nina C Donner
added an update
We perform Phase II clinical trials of an innovative therapy (G-TAK) to treat acute-on-chronic liver failure (#ACLF) and aim to identify reliable #biomarkers for better #PatientStratification and increased survival. End-stage #cirrhosis patients are suffering immensely and are in desperate need of effective treatment, including more awareness and research about novel therapeutic approaches. With G-TAK, one of such novel therapeutic approaches, we are trying to help!
 
Nina C Donner
added an update
Online Educational Event for Patients, 9 June 2021, 3:30 - 5:00 p.m. CEST
The European Liver Patients' Association (ELPA) presents: ‘Therapies for acute decompensation of cirrhosis and ACLF, research needs and outlook’ - The DECISION, MICROB-PREDICT and A-TANGO Online Educational Event for Patients on 9th June 2021, 3.30 - 5.00 p.m. CEST
#ACLF #cirrhosis #noveltherapies
 
Nina C Donner
added an update
On behalf of our scientific coordinator Prof. Rajiv Jalan, concentris research management GmbH, and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), we cordially remind all project partners and scientific and ethical advisory board (SEAB) members of the Kick-off Meeting next week. We are very much looking forward to seeing you all soon (at least virtually)! Let's get this project rolling...
 
Nina C Donner
added an update
The A-TANGO research consortium will work hard over the next 5 years to decrease the mortality rate & increase the survival rate of European patients suffering from severe alcoholic hepatitis (sAH) or ACLF (acute-on-chronic liver failure).
 
Nina C Donner
added an update
The A-TANGO website went live this week. Check it out!
In a few months, we will lift the website to the next level, including descriptions of the project's work packages, detailed member profiles, and valuable information and resources for patients and researchers alike. So swing by once in a while :0).
 
Nina C Donner
added an update
On March 1st, the A-TANGO project started, and we are currently preparing the Kick-Off Meeting on 17 March 2021! Fourteen partners from academia, industry, and patient advocacy join forces in testing a novel combinatorial treatment to prevent ACLF in end-stage liver disease.
 
Nina C Donner
added a project goal
About 30,000 Europeans die every year from alcohol-related cirrhosis. In its final stages, the disease leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.
Scientific Coordination: Prof. Dr. Rajiv Jalan
Principal Investigator: Dr. med. Cornelius Engelmann
Science Communication: Dr. Nina Donner
Project Management: concentris research management gmbh
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945096. This project log reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.